In March XVIII - XIX, MMXXIII, in 8th Annua EBC Biotech Industry colloquium tulit in Suzhou Internationalis Expo Center. Per eventu, in "MMXXII EBC Biotech industria annua Awards" winners fuerunt nuntiatum, cum Hebgene Biopharma accepto in "MMXXII EBC annon Top C C Most Popular Product" Award. Sicut ducens suggestus pro collaboration in biotech industria, EBC fuit obnoxius industria awards pro septem continuos annos, et est cum magna voluptate, ut praesentem EBC Biotech industria annui.
Award lectio processum est coniunctim taxantur per EBC organizing committee et panel de peritorum, qui aestimandam products fundatur in multiple dimensiones, comprehendo user suasiones, quaerere valorem, in aliis. Ex piscinam C conatibus, C products sunt electus ut award recipients.
Hebgene Biopharma honored cum "MMXXII maxime popularibus productum award." Per annum, Hebni, ut dedicated provisor de cellula therapy medicamento solutions, effectum significant Milestones. In turba adeptus Sinis scriptor primum productio permit ad plenum - processus car - T cellula Lorem medicamento, constituendum se ut confidebat socium ad cellulam therapy worldwide. Praeterea, Hebgene Biopharma inked a major consensu cum Encasils ad inchoare currus - NK CDMO project, coniunctim propellentes celeri progressionem intelligentes NK cellula Lorem medicaménta in adventu anno. D. Yongfeng Li, Hebgene scriptor dux venalicium officer, accepit award pro in comitatu.
Post tempus: MMXXIII - III - XXI 00:00:00
